|Home | About | Journals | Submit | Contact Us | Français|
In recent years, abnormal changes in the endocannabinoid system have been found in schizophrenia. The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of schizophrenia, particularly with regards to auditory hallucinations. In this study, we investigated the binding density of cannabinoid CB1 receptors in the STG of schizophrenia patients compared to control subjects.
Quantitative autoradiography was used to investigate the binding densities of [3H]SR141716A (a selective antagonist) and [3H]CP-55940 (an agonist) to the CB1 receptors in the STG. Post-mortem brain tissue was obtained from the NSW Tissue Resource Centre (Australia).
Contrasting to previous findings in the alterations of CB1 receptor densities in the prefrontal, anterior and posterior cingulate cortex of schizophrenia, which were suggested to be associated to impairment of cognition function, no significant difference was found between the schizophrenia and control cases in both [3H]SR141716A and [3H]CP-55940 binding.
We suggest that CB1 receptors in the STG are not involved in the pathology of schizophrenia and the auditory hallucination symptom of this disease.
近年来研究发现, 在精神分裂症患者的内源性大麻素递质系统会出现异常变化, 而颞上回在精神分裂症的病理生理机制中和幻听症状密切相关。 因此, 对照正常人群, 我们研究了精神分裂症患者颞上回大麻素CB-1受体的密度变化。
采用定量放射自显影技术, 通过[3H]SR141716A(CB-1受体选择性拮抗剂)和 [3H]CP-55940(CB-1受体激动剂)检测颞上回CB-1受体密度水平。 死后脑组织由澳大利亚新南威尔士州组织资源中心提供。
先前研究发现, 精神分裂症患者与认知功能失常相关的额前叶, 前、 后扣带回皮质的CB-1 受体密度水平有异常改变. 与此相反, 本研究发现在精神分裂症患者的由[3H]SR141716A和[3H]CP-55940检测的颞上回大麻素受体密度水平和对照组比较没有显著变化。